• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Oncology

RenovoRx prices $12.1M offering

February 7, 2025 By Sean Whooley

RenovoRX RenovoGem drug-delivering pancreatic cancer treatment

RenovoRx (Nasdaq:RNXT) announced that it priced an underwritten public offering of common stock worth proceeds of $12.1 million. Mountain View, California-based RenovoRx priced more than 11.5 million shares of common stock at $1.05 per share. It expects the proceeds to total approximately $12.1 million before deducting underwriting discounts, commissions and offering expenses. The company plans […]

Filed Under: Business/Financial News, Drug-Device Combinations, Funding Roundup, Oncology Tagged With: RenovoRx

Boston Scientific to acquire hepatic artery infusion pump maker Intera Oncology

November 25, 2024 By Sean Whooley

Boston Scientific Intera Oncology

Boston Scientific (NYSE:BSX) announced today that it agreed to acquire infusion pump maker Intera Oncology for an undisclosed amount. Intera Oncology develops the Intera 3000 hepatic artery infusion pump and floxuridine, a chemotherapy drug. Both hold FDA approval. The pump administers hepatic artery infusion (HAI) therapy to treat tumors in the liver primarily caused by […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology Tagged With: Boston Scientific, Intera Oncology

RenovoRx to increase production of RenovoCath catheter delivery system

September 25, 2024 By Sean Whooley

RenovoRx RenovoCath catheter-based delivery system (1)

RenovoRx announced today that it plans to increase the production of its RenovoCath catheter-based delivery system. The Los Altos, California-based company cited increased demand for the delivery of diagnostic and/or therapeutic agents. It signed a new project work order with its principal manufacturing partner, Medical Murray, providing for an expanded relationship. The company looks to […]

Filed Under: Business/Financial News, Drug-Device Combinations, Oncology Tagged With: RenovoRx

Sirtex Medical begins European launch for microsphere delivery system following EU approval

September 16, 2024 By Sean Whooley

Sirtex Siros microsphere delivery system (1)

Sirtex Medical announced today that it received EU MDR certification to market its SIR-Spheres Y-90 resin microspheres and delivery systems. EU MDR authorization enables Woburn, Massachusetts-based Sirtex to kick off a European launch for its Siros delivery system. Siros offers an intuitive, visual and adaptable solution for physicians to administer SIR-Spheres to liver cancer patients. […]

Filed Under: Drug-Device Combinations, Immunotherapy, Oncology, Regulatory/Compliance Tagged With: Sirtex Medical

ICU Medical closes Minnesota facility, cuts 83 jobs

July 16, 2024 By Sean Whooley

This is the logo of ICU Medical.

ICU Medical (Nasdaq: ICUI) filed with the state of Minnesota to confirm the termination of 83 employees following a facility closure. Minnesota’s State Rapid Response Team received a Worker Adjustment and Retraining Notification (WARN) letter from the maker of technologies for infusion therapy, oncology and critical care dated today, July 16. The letter outlined plans to […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Oncology Tagged With: ICU Medical

Carthera wins U.S., EU orphan drug designation for SonoCloud

May 14, 2024 By Sean Whooley

Carthera SonoCloud

Carthera announced today that it received FDA and European orphan drug designation (ODD) for the use of carboplatin with its SonoCloud. The designation allows Paris, France-based Carthera to use carboplatin chemotherapy in the treatment of malignant glioma. Carthera conducts this treatment through the use of SonoCloud, a device that emits ultrasound to temporarily increase the […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Oncology, Pharmaceuticals Tagged With: Carthera, FDA

RenovoRx raises $11.1M to support oncology drug delivery trial

April 15, 2024 By Sean Whooley

RenovoRX RenovoGem drug-delivering pancreatic cancer treatment

RenovoRx (Nasdaq:RNXT) announced today that it closed a private placement worth gross proceeds of approximately $11.1 million. The $11.1 million adds to a separate private placement that brought in proceeds of approximately $6.1 million in January. RenovoRx plans to use the funds to strengthen its balance sheet and extend its cash runway into 2026. Funds […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Oncology Tagged With: RenovoRx

Carthera enrolls first patient in ultrasound drug delivery trial

February 5, 2024 By Sean Whooley

Carthera SonoCloud

Carthera announced today that it enrolled the first patient in the SONOBIRD pivotal trial for its SonoCloud device. Paris, France-based Carthera designed SonoCloud to treat a wide range of brain disorders. The device emits ultrasound to temporarily increase the permeability of blood vessels in the brain, improving therapeutic molecule delivery. After implantation in the skull, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Oncology, Pharmaceuticals Tagged With: Carthera

RenovoRx closes $6.1M private placement

January 29, 2024 By Sean Whooley

RenovoRX RenovoGem drug-delivering pancreatic cancer treatment

RenovoRx announced today that it closed a private placement bringing in gross proceeds of approximately $6.1 million. Los Altos, California-based RenovoRx develops precision oncology therapies based on a local drug delivery platform. Closing this funding round extends the company’s cash runway as it conducts its pivotal TIGer-PaC Phase III clinical trial. It expects the funds […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Oncology Tagged With: RenovoRx

UroGen to raise $120M to support sustained release hydrogel delivery platform

July 28, 2023 By Sean Whooley

UroGen Pharma

UroGen Pharma (Nasdaq:URGN) announced that it entered into a securities purchase agreement worth approximately $120 million. The placement includes the issuance of nearly 12.6 million ordinary shares or pre-funded warrants priced at $9.54 per share. UroGen expects the placement to close on or about today, subject to customary closing conditions. RA Capital Management and Great […]

Filed Under: Business/Financial News, Drug-Device Combinations, Funding Roundup, Hydrogels, Oncology, Pharmaceuticals

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 34
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS